◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › TYRA

Tyra Biosciences, Inc. (TYRA) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-10

Tyra Biosciences, Inc. (TYRA) operates in the Biotechnology industry and is headquartered in Carlsbad, United States with about 87 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, TYRA reported $0M in revenue and ($120M) in net income.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States.

Interactive charts & full statements →

TYRA Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($133M)($104M)($80M)($59M)
Net Income($120M)($86M)($69M)($55M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TYRA Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($42M)($36M)($33M)($32M)($32M)
Net Income($39M)($34M)($30M)($28M)($28M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TYRA Free Cash Flow History

TYRA Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$283M$364M$226M$266M
Total Liabilities$23M$20M$22M$8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TYRA viewer.

Other Companies in Biotechnology

← TYLAll stocksTZOO →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.